• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

mannkind

MannKind inks $61m direct offering of common stock

October 11, 2017 By Sarah Faulkner

MannKind

MannKind (NSDQ:MNKD) said today that it inked a deal with a group of unnamed investors for a registered direct offering of 10,166,600 shares of the company’s common stock for $6.00 apiece. The $61 million offering is slated to close later this week. “With this offering, we have made substantial progress in our efforts to recapitalize […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind, onedrop

MannKind posts mixed Q2

August 8, 2017 By Sarah Faulkner

MannKind

Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind

MannKind combines inhaled insulin with One Drop’s digital diabetes tech

August 7, 2017 By Sarah Faulkner

One Drop

MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: mannkind, onedrop

Anika names medtech veteran as new president | Personnel Moves – July 31, 2017

July 31, 2017 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) last week named medtech veteran Joseph Darling as president, taking over the role from CEO Charles Sherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling. Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx, Anika Therapeutics Inc., Catalent, mannkind, Merrimack Pharmaceuticals, oramedpharmaceuticals

Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017

July 13, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AstraZeneca plc, Avalon, Biogen Idec, cingulatetherapeutics, foamixpharmaceuticals, Gamida Cell, Ipsen, mannkind, milestonescientific, Novaliq GmbH, portal instruments

MannKind inks deal to bring inhaled insulin to Brazil

June 1, 2017 By Sarah Faulkner

MannKind

MannKind Corp. (NSDQ:MNKD) said today that the company inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil. According to the agreement, Biomm will prepare and file the necessary applications for regulatory approval. MannKind will be responsible for manufacturing and supplying Afrezza and Biomm is slated to […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: biomm, mannkind

MannKind shares dip after Q1 sales miss consensus

May 12, 2017 By Sarah Faulkner

MannKind

Shares in MannKind Corp. (NSDQ:MNKD) fell this week after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results. The Valencia, Calif.-based company pared its losses to -$16.3 million on sales of $3 million for the 3 months ended March 31, for bottom-line growth of 53% compared with the same period last year. […]

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind

One Drop, MannKind ink partnership for connected, inhaled diabetes tech

May 5, 2017 By Sarah Faulkner

MannKind

MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]

Filed Under: Big Data, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Respiratory, Wall Street Beat Tagged With: mannkind, onedrop

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS